Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

21. Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy Niv Nivolumab for treating locally advanced olumab for treating locally advanced unresectable or metastatic urothelial unresectable or metastatic urothelial cancer after platinum-containing cancer after platinum-containing chemother chemotherap apy y T echnology appraisal guidance Published: 4 July 2018 nice.org.uk/guidance/ta530 © NICE 2018. All rights reserved. Subject (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

22. Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy (Full text)

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment. The rate of grade ≥3 toxicities from nivolumab monotherapy and radiation-only palliative treatments has been reported at 10% to 18% and 0% to 26%, respectively. We reviewed our experience to assess the acute toxicity (...) profile of concurrent RT-nivolumab.A retrospective review of all consecutive patients from January 2015 to May 2017 who received concurrent RT-nivolumab was conducted at 4 separate centers. Concurrent RT-nivolumab was defined as RT completed between 3 days prior to initial nivolumab infusion and 28 days after the last nivolumab infusion.Of the 261 patients who received nivolumab, 46 (17.6%) had concurrent RT to 67 treatment sites. The median follow-up was 3.3 months (interquartile range, 1.7-6.1

2018 Advances in radiation oncology PubMed

23. Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease (Full text)

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used for the treatment of non-small cell lung cancer (NSCLC) in clinical practice; however, in patients with preexisting ILD, the risk of ICI-related pneumonitis is unknown. We evaluated the efficacy and lung toxicity (...) of nivolumab in patients with NSCLC and ILD.We retrospectively reviewed the medical records of 216 NSCLC patients who had received nivolumab therapy. The existence of ILD in these patients was determined by lung computed tomography findings; 26 patients had ILD. We evaluated the efficacy of nivolumab by measuring the response rate (RR), progression-free survival (PFS) duration, and lung toxicity by incidence, severity, and outcome of nivolumab-related ILD.The RR and median PFS of the ILD and non-ILD groups

2018 Thoracic cancer PubMed

24. Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer (Full text)

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to evaluate the efficacy of nivolumab and of next treatment received after nivolumab progression in patients with advanced NSCLC (...) . Our multicentre retrospective study included all patients receiving nivolumab between January and December 2015. The primary end-point was progression-free survival (PFS) of treatment given after nivolumab. The 303 patients had the following characteristics: median age 63 years, 69% males, 92% smokers, 67% performance status 0-1 and 61% adenocarcinoma. Nivolumab was given as second-line treatment in 40% of patients. With 13.7 months of median follow-up, nivolumab PFS and OS were 2.6 and 11.3

2018 ERJ open research PubMed

25. Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G (Full text)

Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G Little is known about the anti-tumor activity of humoral immunity in lung cancer patients treated with nivolumab, an immune checkpoint inhibitor. Herein, we report a case of lung cancer with 5% expression of PD-L1, in which a partial response to nivolumab was sustained for > 7 months. Immunohistochemical analysis of the metastatic lymph node biopsy (...) specimen showed prominent accumulation of plasma cells and immunoglobulin G. These findings suggest that pre-existing humoral immunity may be worth considering as a candidate therapeutic biomarker of nivolumab in some lung cancer patients.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer PubMed

26. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. (PubMed)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per (...) megabase).We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy

2018 NEJM

27. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. (Full text)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 (...) weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk.A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422

2018 NEJM PubMed

28. Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report (Full text)

Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report The outcome of small cell lung cancer (SCLC) patients is poor because rapid metastasis develops after first-line chemotherapy and few drugs are available for second-line chemotherapy. The median survival rate has not significantly changed in recent years. In this report, we discuss the case of a 71-year-old Chinese female non-smoker diagnosed with extensive-stage (...) SCLC who was treated with nivolumab for a short period and obtained a prolonged clinical benefit. We report the clinical history, clinical features, potential mechanism, benefits, and the best therapeutic window. The patient was treated with transcatheter arterial chemoembolization because of liver metastasis and then with four doses of nivolumab as third-line systemic treatment. There was no disease progression for 15 months. The lesions became larger than before, suggesting disease progression

2018 Thoracic cancer PubMed

29. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic (...) evaluation Edwards S J, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, Masento N & Salih F Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Edwards S J, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, Masento N & Salih F. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma

2018 Health Technology Assessment (HTA) Database.

30. Nivolumab (Opdivo) - metastatic colorectal cancer

Nivolumab (Opdivo) - metastatic colorectal cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 26 January 2018 EMA/51006/2018 EMEA/H/C/003985/II/0030 Withdrawal of the application for a change to the marketing authorisation (...) for Opdivo (nivolumab) On 13 December 2017, Bristol-Myers Squibb Pharma EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application to extend the use of Opdivo to treat colorectal cancer. What is Opdivo? Opdivo is a cancer medicine that contains the active substance nivolumab and is available as a concentrate that is made up into a solution for infusion (drip) into a vein. Opdivo has been authorised since June 2015. It is already used

2018 European Medicines Agency - EPARs

31. Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis (Full text)

Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis To report on a case of uveitis and scleritis resulting as an immune-mediated side effect of cancer immunotherapy with nivolumab and cabiralizumab.Bilateral anterior nongranulomatous anterior uveitis and bilateral diffuse anterior and posterior scleritis occurred following the use of combination cancer immunotherapy. The uveitis and scleritis resolved following temporary (...) discontinuation of nivolumab and cabiralizumab as well as systemic prednisone.Ophthalmologists should be aware of the possibility of acute ocular inflammation developing with cancer immunotherapy. Systemic corticosteroids play a first-line role in managing such immune-mediated side effects.

2018 American journal of ophthalmology case reports PubMed

32. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study (Full text)

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Immune checkpoint inhibitors, including anti-programmed cell death-1 (PD-1) antibodies, have become promising treatments for a variety of advanced malignancies. However, these medicines can cause immune-related adverse events (irAEs), including endocrinopathies.This study examined the incidence of endocrine irAEs induced by nivolumab.Sixty-six patients treated with nivolumab (...) at Nagoya University Hospital were prospectively evaluated for pituitary hormones, thyroid function, antithyroid antibodies (Abs), and glucose levels every 6 weeks after the initiation of nivolumab for 24 weeks.Four out of 66 patients developed destructive thyroiditis, and three patients developed hypothyroidism requiring levothyroxine replacement. The prevalence of positive anti-thyroglobulin Abs (TgAbs) and/or anti-thyroid peroxidase Abs (TPOAbs) at baseline was significantly higher in the group

2018 Journal of the Endocrine Society PubMed

33. [Nivolumab (urothelial carcinoma) - benefit assessment according to õ35a Social Code Book V]

[Nivolumab (urothelial carcinoma) - benefit assessment according to õ35a Social Code Book V] Nivolumab (urothelkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-29 [Nivolumab (urothelial carcinoma) - benefit assessment according to §35a Social Code Book V] Nivolumab (urothelkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-29 [Nivolumab (urothelial carcinoma) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (urothelkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-29. [Nivolumab (urothelial carcinoma) - benefit assessment according to §35a Social Code Book V] Cologne

2018 Health Technology Assessment (HTA) Database.

34. [Nivolumab (squamous cell carcinoma of the head and neck). Second addendum to A-17-24]

[Nivolumab (squamous cell carcinoma of the head and neck). Second addendum to A-17-24] Nivolumab (plattenepithelkarzinom des kopf-hals-nereichs): 2. Addendum zum auftrag A17-24; auftrag G17-10 [Nivolumab (squamous cell carcinoma of the head and neck). Second addendum to A-17-24] Nivolumab (plattenepithelkarzinom des kopf-hals-nereichs): 2. Addendum zum auftrag A17-24; auftrag G17-10 [Nivolumab (squamous cell carcinoma of the head and neck). Second addendum to A-17-24] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (plattenepithelkarzinom des kopf-hals-nereichs): 2. Addendum zum auftrag A17-24; auftrag G17-10. [Nivolumab (squamous cell carcinoma of the head and neck). Second addendum to A-17-24] Cologne

2018 Health Technology Assessment (HTA) Database.

35. [Nivolumab (squamous cell carcinoma of the head and neck) - addendum to Commission A17-24 ]

[Nivolumab (squamous cell carcinoma of the head and neck) - addendum to Commission A17-24 ] Nivolumab (plattenepithelkarzinom des kopf-hals-bereichs): addendum zum auftrag A17-24; Auftrag A17-54 [Nivolumab (squamous cell carcinoma of the head and neck) - addendum to Commission A17-24 ] Nivolumab (plattenepithelkarzinom des kopf-hals-bereichs): addendum zum auftrag A17-24; Auftrag A17-54 [Nivolumab (squamous cell carcinoma of the head and neck) - addendum to Commission A17-24 ] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (plattenepithelkarzinom des kopf-hals-bereichs): addendum zum auftrag A17-24; Auftrag A17-54. [Nivolumab (squamous cell carcinoma of the head and neck) - addendum

2018 Health Technology Assessment (HTA) Database.

36. [Nivolumab (melanoma) - benefit assessment according to õ35a Social Code Book V (expiry of the decision)]

[Nivolumab (melanoma) - benefit assessment according to õ35a Social Code Book V (expiry of the decision)] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); auftrag A17-27 [Nivolumab (melanoma) - benefit assessment according to §35a Social Code Book V (expiry of the decision)] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); auftrag A17-27 [Nivolumab (melanoma) - benefit assessment according to §35a Social Code Book V (expiry of the decision (...) )] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); auftrag A17-27. [Nivolumab (melanoma) - benefit assessment according to §35a Social Code Book

2018 Health Technology Assessment (HTA) Database.

37. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Cabozantinib is likely to be the best treatment to delay tumour growth and prolong life, followed by nivolumab, but all treatments delayed disease progression and prolonged survival compared with best supportive care. {{author}} {{($index , , , , , , & . Steve J Edwards

2018 NIHR HTA programme

38. Nivolumab (Opdivo) for urothelial carcinoma

Nivolumab (Opdivo) for urothelial carcinoma 1 Cost-effectiveness of nivolumab (Opdivo®) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum- containing chemotherapy The NCPE has issued a recommendation regarding the cost-effectiveness of nivolumab (Opdivo®). Following assessment of the Applicant’s submission, the NCPE recommends that nivolumab (Opdivo®) not be considered for reimbursement. This recommendation should (...) be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (BMS) economic dossier on the cost effectiveness of nivolumab (Opdivo®). The NCPE uses a decision framework to systematically assess whether a technology is cost-effective. This includes clinical effectiveness and health related quality of life benefits, which the new

2018 Pediatric Endocrine Society

39. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057 (...) ; ClinicalTrials.gov identifier: NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results, including a pooled analysis of the two studies. Methods Patients with stage IIIB/IV squamous (N = 272) or nonsquamous (N = 582) NSCLC and disease progression during or after prior platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks). Minimum follow-up for survival was 24.2 months. Results Two-year overall survival rates

2017 EvidenceUpdates

40. Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76

Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76 1 Translation of addendum A17-21 Nivolumab (klassisches Hodgkin-Lymphom) – Addendum zum Auftrag A16-76 (Version 1.0; Status: 24 May 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 24 May 2017 1.0 Commission: A17-21 Version: Status: IQWiG Reports – Commission No. A17-21 (...) Nivolumab (classical Hodgkin lymphoma) – Addendum to Commission A16-76 1 Addendum A17-21 Version 1.0 Nivolumab – Addendum to Commission A16-76 24 May 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (classical Hodgkin lymphoma) – Addendum to Commission A16-76 Commissioning agency: Federal Joint Committee Commission awarded on: 11 May 2017 Internal Commission No.: A17-21 Address

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)